Clearside Biomedical, Inc. (CLSD), Wednesday said its ODYSSEY Phase 2b study of CLS-AX for the treatment of neovascular age-related macular degeneration (wet AMD) achieved primary goal. The company's shares were trading up more than 25 percent in pre-market activity.
In the ODYSSEY Phase 2b study, participants with wet AMD were randomized to receive either CLS-AX or standard of care therapy, aflibercept. The study achieved its primary goal of maintaining stable best corrected visual acuity (BCVA) throughout the trial. In participants who received CLS-AX, BCVA and ocular anatomy (central subfield thickness) were stable up to 6 months compared to participants who received aflibercept. About 67 percent of participants who received CLS-AX did not require any additional treatment up to 6 months. The study also met its secondary goals.
Additionally, the drug was well tolerated and no ocular or treatment-related serious adverse events were reported.
A Phase 3 study of CLS-AX in wet AMD is underway.
Clearside Biomedical stock had closed at $1.48, down 6.33 percent on Tuesday. It has traded in the range of $0.6500 - $2.1200 in the last 1 year.
For comments and feedback: editorial@rttnews.com